bsNAb pretargeting therapy (IBC)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NamebsNAb pretargeting therapy (IBC)

Drug Alias Name99mTc-divalent-HSG-peptideBS1.5hBS14trivalent bispecific fusion proteins (IBC)yttrium-90-DOTA-divalent-HSG-peptide +[14]

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulatorsB-lymphocyte antigen CD20 inhibitors

TargetsCarcinoembryonic antigen related cell adhesion molecule 5B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-HodgkinNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesIbc Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIbc Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinNeoplasms

Other Information

ATC CodeN/A